Skip to main content

Advertisement

Table 4 Details of included observational studies*

From: Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Reference Jacobs 2009 Akagi 2008 Channick 2006 Hoeper 2003 Mathai 2007 Hoeper 2004
Baseline therapy ERA + PDE5i Pr ERA Pr ERA None
Add-on therapy Pr ERA Pr ERA PDE5i ERA
Prostacyclin analogue intravenous epoprostenol and subcutaneous treprostinil intravenous epoprostenol inhaled treprostinil oral beraprost and inhaled iloprost NA NA
Treatment dose 10-20 ng/kg/min subcutaneous treprostinil, 38.4 end of observation. 6-8 ng/kg/min intravenous epoprostenol, 16.2 end of observation 62.5 mg bosentan twice daily 6 on 30 mcg inhaled treprostinil 4 daily 6 on 45 mug 4 daily. 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks. 20 mg sildenafil (up to 100 mg included) once daily 62.5 mg bosentan twice daily, increased to 125 mg twice daily after 4 weeks.
Patients at end of study 10 7 11 20 25 9
Duration 16 weeks 1 year 12 weeks 6 months 12 weeks 3 months
Change 6MWD 41 (38) 3 (23) 67 (45) 58 (9.6) 20 (28) 57 (35)
Baseline 6MWD 387 (30) 392 (16) 339 (26) 346 (23.7) 265 (19) 346
Age 37 32 51.2 46 56.2 39
Sex (% male) 0.19 0.13 0.09 0.30 0.04 0.22
STATUS 3 2 3 3.2 3.1 3.1
PVR 957.8¶ 776 744 1147 928 1549
  1. *ERA are endothelin receptor antagonists, PDE5i are phosphodiesterase 5 inhibitors, Pr are prostacyclin analogues. iv ep is intravenous epoprostenol, inh ilp is inhaled iloprost, sc trep is subcutaneous treprostinil.
  2. ¶Imputed from linear model for PVR based on Age, right arterial pressure, MPAP and cardiac output.